RP-3 is under clinical development by Replimune and currently in Phase I for Osteosarcoma. According to GlobalData, Phase I drugs for Osteosarcoma have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how RP-3’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RP-3 is under development for the treatment of advanced solid tumors including head and neck cancer, lung cancer, breast cancer, gastric cancer, recurrent head and neck cancer squamous cell carcinoma, oral cavity cancer, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer, metastatic hepatocellular carcinoma, micro-satellite stable colorectal cancer (CRC), melanoma and liver metastases, soft tissue sarcomas including leiomyosarcoma, osteosarcoma, chondrosarcoma, myxofibrosarcoma and epithelioid sarcomas. RP3 is a genetically modified herpes simplex type 1 virus (HSV-1) that expresses exogenous genes (anti-CTLA-4 antibody, 4-1BB ligand and CD40 ligand). It is administered by intratumor route. The drug candidate is an oncolytic immunotherapy and is developed based on Immulytic platform.
For a complete picture of RP-3’s drug-specific PTSR and LoA scores, buy the report here.